188 related articles for article (PubMed ID: 26992916)
1. Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype.
Bergström SH; Rudolfsson SH; Bergh A
Neoplasia; 2016 Mar; 18(3):152-61. PubMed ID: 26992916
[TBL] [Abstract][Full Text] [Related]
2. Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants.
Jernberg E; Thysell E; Bovinder Ylitalo E; Rudolfsson S; Crnalic S; Widmark A; Bergh A; Wikström P
PLoS One; 2013; 8(11):e77407. PubMed ID: 24244276
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
Nordstrand A; Bergström SH; Thysell E; Bovinder-Ylitalo E; Lerner UH; Widmark A; Bergh A; Wikström P
Clin Exp Metastasis; 2017 Apr; 34(3-4):261-271. PubMed ID: 28447314
[TBL] [Abstract][Full Text] [Related]
4. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
5. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
7. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment.
Morrissey C; Brown LG; Pitts TE; Vessella RL; Corey E
Neoplasia; 2010 Feb; 12(2):192-205. PubMed ID: 20126477
[TBL] [Abstract][Full Text] [Related]
8. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
Bogdanos J; Karamanolakis D; Tenta R; Tsintavis A; Milathianakis C; Mitsiades C; Koutsilieris M
Endocr Relat Cancer; 2003 Jun; 10(2):279-89. PubMed ID: 12790789
[TBL] [Abstract][Full Text] [Related]
9. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
[TBL] [Abstract][Full Text] [Related]
10. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.
Park SH; Keller ET; Shiozawa Y
Calcif Tissue Int; 2018 Feb; 102(2):152-162. PubMed ID: 29094177
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
[TBL] [Abstract][Full Text] [Related]
13. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis.
Ye X; Huang X; Fu X; Zhang X; Lin R; Zhang W; Zhang J; Lu Y
J Hematol Oncol; 2023 May; 16(1):46. PubMed ID: 37138326
[TBL] [Abstract][Full Text] [Related]
15. Cyclin A1 and P450 Aromatase Promote Metastatic Homing and Growth of Stem-like Prostate Cancer Cells in the Bone Marrow.
Miftakhova R; Hedblom A; Semenas J; Robinson B; Simoulis A; Malm J; Rizvanov A; Heery DM; Mongan NP; Maitland NJ; Allegrucci C; Persson JL
Cancer Res; 2016 Apr; 76(8):2453-64. PubMed ID: 26921336
[TBL] [Abstract][Full Text] [Related]
16. Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer.
van der Sluis TM; Bijnsdorp IV; Jacobs JJ; Meuleman EJ; Rozendaal L; Geldof AA; van Moorselaar RJ; Vis AN
World J Urol; 2013 Apr; 31(2):261-6. PubMed ID: 23080125
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.
Zhang X; Morrissey C; Sun S; Ketchandji M; Nelson PS; True LD; Vakar-Lopez F; Vessella RL; Plymate SR
PLoS One; 2011; 6(11):e27970. PubMed ID: 22114732
[TBL] [Abstract][Full Text] [Related]
18. Bone-targeting agents in prostate cancer.
Suzman DL; Boikos SA; Carducci MA
Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
[TBL] [Abstract][Full Text] [Related]
19. The Bone Microenvironment in Prostate Cancer Metastasis.
DiNatale A; Fatatis A
Adv Exp Med Biol; 2019; 1210():171-184. PubMed ID: 31900910
[TBL] [Abstract][Full Text] [Related]
20. Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone.
Sharma S; Xing F; Liu Y; Wu K; Said N; Pochampally R; Shiozawa Y; Lin HK; Balaji KC; Watabe K
J Biol Chem; 2016 Sep; 291(37):19351-63. PubMed ID: 27422817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
